Literature DB >> 10508127

Aminopeptidase activities in breast cancer tissue.

J M Martínez1, I Prieto, M J Ramírez, C Cueva, F Alba, M Ramírez.   

Abstract

BACKGROUND: Endopeptidases such as cathepsins help determine the prognosis of breast cancer (BC). However, little information is available about the role in BC of aminopeptidases (APs), which have been implicated in the metabolism of several local hormonal factors.
METHODS: Using aminoacyl-beta-naphthylamides as substrates, we measured fluorometrically alanyl-AP, arginyl-AP, cystinyl-AP, glutamyl-AP, aspartyl-AP, and pyroglutamyl-AP activities in their soluble and membrane-bound forms in surgically removed BC tissue from which we separated samples of neoplastic, adjacent tumoral, and unaffected surrounding tissue.
RESULTS: Compared with unaffected tissue, neoplastic tissue had significantly higher activities of soluble alanyl-AP (553.9 +/- 82.8 vs 1615.2 +/- 183.0 pmol/mg protein; P <0.001), arginyl-AP (372.4 +/- 56.6 vs 1027.2 +/- 143.5 pmol/mg protein; P <0.001), and cystinyl-AP (74.8 +/- 10.0 vs 282.9 +/- 37.2 pmol/mg protein; P <0.001), and of membrane-bound arginyl-AP (457.7 +/- 97.9 vs 886.6 +/- 140.0 pmol/mg protein; P <0.01). However, membrane-bound aspartyl-AP activity was significantly lower in neoplastic tissue (17.3 +/- 1.4 vs 9.2 +/- 1.2 pmol/mg protein; P <0.05) and pyroglutamyl-AP activity was significantly lower in neoplastic and adjacent tissues (12.8 +/- 0.9 vs 7.0 +/- 1. 2 and 8.0 +/- 1.3 pmol/mg protein; P <0.001 for both comparisons).
CONCLUSIONS: The present results document changes in AP activities in BC tissue. These changes may reflect the functional status of the AP substrates, which can be selectively activated or inhibited locally in the affected tissue as a result of specific conditions brought about by the tumor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508127

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  17 in total

1.  Differential exoprotease activities confer tumor-specific serum peptidome patterns.

Authors:  Josep Villanueva; David R Shaffer; John Philip; Carlos A Chaparro; Hediye Erdjument-Bromage; Adam B Olshen; Martin Fleisher; Hans Lilja; Edi Brogi; Jeff Boyd; Marta Sanchez-Carbayo; Eric C Holland; Carlos Cordon-Cardo; Howard I Scher; Paul Tempst
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

2.  Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients.

Authors:  Irena Ranogajec; Jasminka Jakić-Razumović; Velibor Puzović; Jelka Gabrilovac
Journal:  Med Oncol       Date:  2011-05-25       Impact factor: 3.064

3.  Hypothalamus-pituitary-thyroid axis disruption in rats with breast cancer is related to an altered endogenous oxytocin/insulin-regulated aminopeptidase (IRAP) system.

Authors:  María Pilar Carrera-González; María Jesús Ramírez-Expósito; Jose Manuel Arias de Saavedra; Rafael Sánchez-Agesta; María Dolores Mayas; Jose Manuel Martínez-Martos
Journal:  Tumour Biol       Date:  2011-01-05

4.  Mammary renin-angiotensin system-regulating aminopeptidase activities are modified in rats with breast cancer.

Authors:  Maria del Pilar Carrera; Maria Jesus Ramírez-Expósito; Maria Dolores Mayas; Maria Jesus García; Jose Manuel Martínez-Martos
Journal:  Tumour Biol       Date:  2010-07-21

5.  Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors.

Authors:  Qian Liu; Hang Dong; Wei Zhao; Guozhen Zhang; Shunda Li; Qifu Xu; Yingjie Zhang
Journal:  ACS Med Chem Lett       Date:  2021-11-10       Impact factor: 4.345

6.  Discovery of Novel Tetrahydro-β-carboline Containing Aminopeptidase N Inhibitors as Cancer Chemosensitizers.

Authors:  Xiaoyan Xing; Fahui Li; Yajie Hu; Lin Zhang; Qian Hui; Hongyu Qin; Qixiao Jiang; Wenyan Jiang; Chunyan Fang; Lei Zhang
Journal:  Front Oncol       Date:  2022-05-23       Impact factor: 5.738

7.  Monitoring peptidase activities in complex proteomes by MALDI-TOF mass spectrometry.

Authors:  Josep Villanueva; Arpi Nazarian; Kevin Lawlor; Paul Tempst
Journal:  Nat Protoc       Date:  2009-07-23       Impact factor: 13.491

8.  The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.

Authors:  Malin Wickström; Caroline Haglund; Henrik Lindman; Peter Nygren; Rolf Larsson; Joachim Gullbo
Journal:  Invest New Drugs       Date:  2007-10-06       Impact factor: 3.850

9.  Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan; Vincenzo Costigliola; Daniela Trog; Michael Braun; Manuel Debald; Walther Kuhn; Hans H Schild
Journal:  EPMA J       Date:  2013-02-19       Impact factor: 6.543

10.  CD13 is a useful tool in the differential diagnosis of meningiomas with potential biological and prognostic implications.

Authors:  Stefano Marletta; Claudio Luchini; Nicola Sperandio; Evelin Torresani; Alessandro Sorio; Ilaria Girolami; Aldo Scarpa; Albino Eccher; Claudio Ghimenton
Journal:  Virchows Arch       Date:  2022-02-25       Impact factor: 4.535

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.